Stephens downgraded Avanos Medical from Overweight to Equal-Weight and set a new price target of $45.00 from $60.00 previously
Get the next $AVNS alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $AVNS
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 5/22/2023 | $31.00 | Buy | CL King |
| 2/24/2022 | $47.00 → $41.00 | Overweight | Keybanc |
| 1/7/2022 | $37.00 → $36.00 | Underweight | Morgan Stanley |
| 8/4/2021 | $45.00 → $41.00 | Underweight | Morgan Stanley |
| 8/4/2021 | $60.00 → $45.00 | Overweight → Equal-Weight | Stephens |
| 8/4/2021 | $55.00 → $47.00 | Overweight | Keybanc |
Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer
ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2024 Results
ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2024 results. "We are pleased with our fourth quarter results, which delivered 5% organic growth and continued execution on each of our transformation initiative priorities," said Michael Greiner, Avanos's interim chief executive officer. Greiner continued, "For the full year, we generated $83 million of free cash flow and $108 million of adjusted EBITDA. We currently have net debt of approximately $20 million. We believe our strong financial position wil
Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
ALPHARETTA, Ga., Feb. 19, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2024 on Wednesday, Feb. 26 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Michael Greiner, interim chief executive officer and Scott Galovan, senior vice president, strategy and corporate development. To instantly join the conference call by phone, use the following link to
Avanos Medical downgraded by KeyBanc Capital Markets
KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight
CL King initiated coverage on Avanos Medical with a new price target
CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00
Keybanc reiterated coverage on Avanos Medical with a new price target
Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously
Shimer Julie Ann bought $9,925 worth of shares (500 units at $19.85), increasing direct ownership by 1% to 50,090 units (SEC Form 4)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
SVP, General Counsel James Mojirade was granted 19,201 shares, increasing direct ownership by 28% to 88,218 units (SEC Form 4)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
Principal Accounting Officer Hurley John Joseph was granted 1,961 shares, increasing direct ownership by 20% to 11,709 units (SEC Form 4)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
SVP, Chief Commercial Officer Holbrook Kerr was granted 22,877 shares, increasing direct ownership by 30% to 98,860 units (SEC Form 4)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
Avanos Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)
SEC Form DEFA14A filed by Avanos Medical Inc.
DEFA14A - AVANOS MEDICAL, INC. (0001606498) (Filer)
SEC Form DEF 14A filed by Avanos Medical Inc.
DEF 14A - AVANOS MEDICAL, INC. (0001606498) (Filer)
Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer
ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support
Avanos Medical, Inc. Appoints Indrani Franchini to Board of Directors
ALPHARETTA, Ga., July 1, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors. "We are excited to welcome Indrani Franchini to the Avanos board," remarked Gary Blackford, Avanos board chair. "Her experience with a broad range of global companies will be invaluable to Avanos as we pursue our vision of getting patients back to the things that matter." "Avanos is committed to addressing some of today's most important healthcare needs and I am thrilled to join it
Avanos Medical, Inc. Appoints Sig Delgado as Senior Vice President, Integrated Supply Chain
ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain. In this role, Delgado will lead the teams focused on implementing continuous improvements within the Company's end-to-end supply chain capabilities worldwide. Delgado joins Avanos from Jabil Healthcare, the industry's largest global provider of healthcare manufacturing solutions, where he most recently served as vice president of its global medical technology business. His background includ
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2024 Results
ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2024 results. "We are pleased with our fourth quarter results, which delivered 5% organic growth and continued execution on each of our transformation initiative priorities," said Michael Greiner, Avanos's interim chief executive officer. Greiner continued, "For the full year, we generated $83 million of free cash flow and $108 million of adjusted EBITDA. We currently have net debt of approximately $20 million. We believe our strong financial position wil
Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
ALPHARETTA, Ga., Feb. 19, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2024 on Wednesday, Feb. 26 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Michael Greiner, interim chief executive officer and Scott Galovan, senior vice president, strategy and corporate development. To instantly join the conference call by phone, use the following link to
Avanos Medical, Inc. Announces Third Quarter 2024 Results, retirement of CEO
ALPHARETTA, Ga., Oct. 30, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. Gary Blackford, Avanos Board Chairman, noted, "Joe has decided to retire after leading Avanos for the past seven years. Joe has agreed to assist the Company in the transition of leadership, and will continue to consult with the Company through April of next year. Avanos is better positioned financially and organizationally today to achieve its longer-term value creation goals because of Joe's lea
SEC Form SC 13G filed by Avanos Medical Inc.
SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)
SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)